Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom.
Department of Radiology, University of Cambridge, Cambridge, United Kingdom.
Eur Radiol. 2024 Oct;34(10):6217-6226. doi: 10.1007/s00330-024-10770-z. Epub 2024 Apr 24.
Active surveillance (AS) is the preferred option for patients presenting with low-intermediate-risk prostate cancer. MRI now plays a crucial role for baseline assessment and ongoing monitoring of AS. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations aid radiological assessment of progression; however, current guidelines do not advise on MRI protocols nor on frequency. Biparametric (bp) imaging without contrast administration offers advantages such as reduced costs and increased throughput, with similar outcomes to multiparametric (mp) MRI shown in the biopsy naïve setting. In AS follow-up, the paradigm shifts from MRI lesion detection to assessment of progression, and patients have the further safety net of continuing clinical surveillance. As such, bpMRI may be appropriate in clinically stable patients on routine AS follow-up pathways; however, there is currently limited published evidence for this approach. It should be noted that mpMRI may be mandated in certain patients and potentially offers additional advantages, including improving image quality, new lesion detection, and staging accuracy. Recently developed AI solutions have enabled higher quality and faster scanning protocols, which may help mitigate against disadvantages of bpMRI. In this article, we explore the current role of MRI in AS and address the need for contrast-enhanced sequences. CLINICAL RELEVANCE STATEMENT: Active surveillance is the preferred plan for patients with lower-risk prostate cancer, and MRI plays a crucial role in patient selection and monitoring; however, current guidelines do not currently recommend how or when to perform MRI in follow-up. KEY POINTS: Noncontrast biparametric MRI has reduced costs and increased throughput and may be appropriate for monitoring stable patients. Multiparametric MRI may be mandated in certain patients, and contrast potentially offers additional advantages. AI solutions enable higher quality, faster scanning protocols, and could mitigate the disadvantages of biparametric imaging.
主动监测(AS)是低中危前列腺癌患者的首选方案。MRI 现在在基线评估和 AS 的持续监测中发挥着关键作用。前列腺癌放射学变化连续评估(PRECISE)建议有助于对进展进行放射学评估;然而,目前的指南既不建议 MRI 方案,也不建议频率。不进行对比剂增强的双参数(bp)成像具有降低成本和提高通量的优势,并且在活检初筛环境中与多参数(mp)MRI 具有相似的结果。在 AS 随访中,范式从 MRI 病灶检测转变为进展评估,并且患者有继续进行临床监测的进一步安全网。因此,bpMRI 可能适用于常规 AS 随访路径中临床稳定的患者;然而,目前针对这种方法的证据有限。需要注意的是,在某些患者中可能需要 mpMRI,并且它可能具有额外的优势,包括改善图像质量、新病灶检测和分期准确性。最近开发的人工智能解决方案使更高质量和更快的扫描协议成为可能,这可能有助于减轻 bpMRI 的缺点。在本文中,我们探讨了 MRI 在 AS 中的当前作用,并解决了对增强序列的需求。临床相关性声明:主动监测是低危前列腺癌患者的首选方案,MRI 在患者选择和监测中起着至关重要的作用;然而,目前的指南目前并不建议在随访中如何或何时进行 MRI。关键点:无对比剂双参数 MRI 降低了成本并提高了通量,可能适用于监测稳定的患者。在某些患者中可能需要进行多参数 MRI,并且对比剂可能具有额外的优势。人工智能解决方案可以实现更高质量、更快的扫描协议,并可能减轻双参数成像的缺点。